National Consultation on Nepal’s Graduation from the LDC Category, Implementation of IPoA and SDGs Held

National Consultation on Nepal’s Graduation from the LDC Category, Implementation of IPoA and SDGs Held


Details

Pharmaceutical Waiver Extension: A 17-year Deal Reached

Published Date: January 21, 2022, at 7:15 am

Our year-long advocacy for an indefinite transition period of exemption/waiver to LDCs for pharmaceutical products has now ended with the final deal reached! Please see attached, the statement we have released critiquing the deal.

 

Yesterday 6th November, the WTO TRIPS Council adopted the decision to grant 17-year transition period of exemption/waiver to LDCs regarding pharmaceutical products. We have expressed our disappointment and critique over this weak deal which is only 3 years more compared to the existing one (which ends this year) of 14 years granted in 2001. We had been advocating for an indefinite transition period of exemption/waiver, until a country exits the LDC category, given continual gross health challenges in LDCs.

 

FileFile size
Download this file (ldcwatch statement on ldc trips pharmaceutical 17yr extens.pdf)

LDC Watch statement on ldc trips pharmaceutical 17yr extens

170 kB

Facebook

Contact Us  

Contact LDC Watch

International Secretariat

LDC Watch

P.O.Box: 8130, 288 Gairidhara Marg, Gairidhara

Kathmandu, Nepal

Tel: +977 1 4004507, 4004985, 4004976

Fax: +977 1 4004508

E-mail: ldcwatch@ldcwatch.org

Web: www.ldcwatch.org

 

 

European Co-ordination Office

115 Rue Stevin, B – 1000, Brussels, Belgium

Tel: +322 231 1659

Fax: +322 230 3780

Google Map Location: